Expression of type 8 capsular polysaccharide and production of toxic shock syndrome toxin 1 are associated among vaginal isolates of Staphylococcus aureus.
about
Effects of in vitro and in vivo growth conditions on expression of type 8 capsular polysaccharide by Staphylococcus aureusStaphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence.Capsule expression by bovine isolates of Staphylococcus aureus from Argentina: genetic and epidemiologic analyses.Genetic and serologic evaluation of capsule production by bovine mammary isolates of Staphylococcus aureus and other Staphylococcus spp. from Europe and the United States.Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolatesStaphylococcus aureus Cap5O has UDP-ManNAc dehydrogenase activity and is essential for capsule expression.Characterization of the structure and biological functions of a capsular polysaccharide produced by Staphylococcus saprophyticusCapsule-negative Staphylococcus aureus induces chronic experimental mastitis in mice.Structural and biological characterization of a capsular polysaccharide produced by Staphylococcus haemolyticus.Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis.Staphylococcus aureus capsular polysaccharides.USA300 and USA500 clonal lineages of Staphylococcus aureus do not produce a capsular polysaccharide due to conserved mutations in the cap5 locus.Differential abilities of capsulated and noncapsulated Staphylococcus aureus isolates from diverse agr groups to invade mammary epithelial cells.Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests.Genetic analysis of type 5 capsular polysaccharide expression by Staphylococcus aureus.Dynamic in vivo mutations within the ica operon during persistence of Staphylococcus aureus in the airways of cystic fibrosis patients.Characterization of a new variant of IS257 that has displaced the capsule genes within bovine isolates of Staphylococcus aureus.Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes.Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice.Virulence of Staphylococcus aureus mutants altered in type 5 capsule production.Capsule expression and genotypic differences among Staphylococcus aureus isolates from patients with chronic or acute osteomyelitis.Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis.The Staphylococcus aureus polysaccharide capsule and Efb-dependent fibrinogen shield act in concert to protect against phagocytosis.Salicylic acid diminishes Staphylococcus aureus capsular polysaccharide type 5 expressionAntibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo.Rapid and reliable identification of Staphylococcus aureus capsular serotypes by means of artificial neural network-assisted Fourier transform infrared spectroscopy.Characteristics of Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Strains Isolated from Skin and Soft-Tissue Infections in Uruguay.Molecular fingerprinting of Staphylococcus aureus isolated from patients with osteomyelitis in Argentina and clonal distribution of the cap5(8) genes and of other selected virulence genes.Mutation of Agr Is Associated with the Adaptation of Staphylococcus aureus to the Host during Chronic Osteomyelitis.
P2860
Q33595610-00A87832-BA34-43DC-9128-F66732D7EF9CQ33788238-8DB76686-1F53-43CA-90CE-B2F94A445FF3Q33965596-5309F1D0-0CEC-40A8-91AC-D92FE5A06BF6Q33968870-1CE9A82A-AFFA-4E96-8E92-903AD2E36C12Q33978642-D76BB3B0-86F2-48F3-A9EF-674BE8E865FBQ34005978-B16A7E32-8E31-4E90-B5AD-2EFA25672645Q34119229-487B1475-7CD9-4907-ABD7-5AB8B13ED6E2Q34194538-B1142B7D-6F2F-4E78-9013-DD9DFBFA8063Q34731479-E65287F5-7B1F-4C23-B82B-E1DF882ADBEDQ35382289-A6AC8F63-5437-4EE1-B722-1A623C8135D6Q35630504-D42F93F0-9455-4A64-86DE-3FE039DACDA8Q35677495-6768D49F-6E8A-400A-A6E6-16D82DC66BE9Q35689224-91251AFF-3753-4BB6-9BAD-7E297E04A4CBQ35690743-55C31D90-A3E3-4067-A159-68B8A48A36D5Q35967916-0E4C8AFC-F81F-4A3A-8A29-BCB5FCF19A8BQ36208337-FB0A4185-86FF-43CC-AC97-ED7D5409093FQ36313848-3EB0BDF6-7FFA-43E4-A2E6-85B73C1E721AQ36942862-4C7768CD-17E2-4A4C-8FA5-57558410CE55Q36974423-0F688917-2470-4D82-B28D-BD3331D3E2EAQ36974536-264AA41F-5349-435A-913E-8B275231B845Q37191404-84B9A655-1584-4888-823B-9AA8CAD928BCQ37548140-D8EC1603-9687-4229-85FC-95E2A40A5C51Q38876259-B0B0106B-CCDE-49F8-9D73-A7F5276574B2Q39763551-BF959985-45BD-47CA-A465-448C2B87B434Q40416064-20C9826B-1923-451F-9D19-3174E5E54E0BQ41428438-2DAC314A-0189-40A5-A403-EC5FA1BAFF1CQ41977222-7A0C4D5A-F095-4F8E-BE0D-C2B84D3F1B7DQ42282283-A38E6CDC-2636-4797-8208-F57122BA7425Q49866203-6059A574-5B95-4AB6-A569-7FAB5133B7DB
P2860
Expression of type 8 capsular polysaccharide and production of toxic shock syndrome toxin 1 are associated among vaginal isolates of Staphylococcus aureus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 1990
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Expression of type 8 capsular ...... ates of Staphylococcus aureus.
@en
Expression of type 8 capsular ...... ates of Staphylococcus aureus.
@nl
type
label
Expression of type 8 capsular ...... ates of Staphylococcus aureus.
@en
Expression of type 8 capsular ...... ates of Staphylococcus aureus.
@nl
prefLabel
Expression of type 8 capsular ...... ates of Staphylococcus aureus.
@en
Expression of type 8 capsular ...... ates of Staphylococcus aureus.
@nl
P2093
P2860
P1476
Expression of type 8 capsular ...... ates of Staphylococcus aureus.
@en
P2093
P2860
P304
P407
P577
1990-12-01T00:00:00Z